ScientificMed is a Swedish digital therapeutics (DTx) company that improves the treatment results and quality of life of cancer patients. The great advantage of their innovative and cloud-based patient engagement platform SciMedOne – is that it allows a closer interaction between the patient and its cancer care team, including a systematic analysis of various real-world facts related to the drug therapies given, and their efficacy and safety, as well as other treatments. All centered around the patient’s experience and challenges, aiming to improve disease management in all aspects on an individual basis.
Collecting and systematically analyzing real world patient data will play an increasing role in drug development, market approvals, pricing and reimbursements. The role of Real World Data in drug development and market approvals is expanding especially in oncology as the prevalence of cancer is continuously increasing and overtaking cardiovascular disease in the U.S.
Partners and customers are pharmaceutical companies, healthcare providers, integrators and academia, among others.
Business proof of concept – Existing business with Big Pharma customers, incl. AstraZeneca, Novartis, and one leading pharma company within immune-oncology, generating initial revenue streams
Experia Corporate Finance Advisors was mandated to assist in the sale of ScientificMed. The pandemic has in 2020 rapidly increased the adoption of digital health technologies and boosted the digital health industry growth. ScientificMed has recently demonstrated that it can meet clinical as well as business values – and is now ready to proceed to the next step of the commercialization of their product. With a proven platform and concept, our ScientificMed was ready to take advantage of the global transition to digital care and was seeking a buyer to extend its reach globally, as the preferred digital therapeutics within cancer care.
Experia corporate finance advisors acted as exclusive M&A advisor to ScientificMed and supported its client throughout the entire transaction. Through the acquisition of ScientificMed, Cuviva takes an active and leading role in the development of a comprehensive range of values that includes both broad solutions for distance monitoring and follow-up of chronically ill and specialized digital therapies in oncology today, and subsequently more specific diagnostic areas.